Global Lupus Therapeutics Market to Reach $6.7 Billion by 2030
The global market for Lupus Therapeutics estimated at US$3.4 Billion in the year 2022, is projected to reach a revised size of US$6.7 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2022-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 8.3% CAGR for the next 8-year period.The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 8.2% CAGR
The Lupus Therapeutics market in the U.S. is estimated at US$1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 7.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.Select Competitors (Total 17 Featured) -
- ADMA Biologics, Inc.
- Amgen, Inc.
- Anthera Pharmaceuticals, Inc.
- Bayer Healthcare AG
- Biogen, Inc.
- Biotest AG
- Bristol-Myers Squibb Company
- Celgene Corporation
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Kedrion Biopharma, Inc.
- LFB Group
- MedImmune, LLC
- Merck KgaA
- Novartis International AG
- Pfizer, Inc.
- Shire PLC
- Takeda Pharmaceuticals Company Ltd.
- UCB SA
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for Lupus Therapeutics
What is the estimated value of the Global Market for Lupus Therapeutics?
What is the growth rate of the Global Market for Lupus Therapeutics?
What is the forecasted size of the Global Market for Lupus Therapeutics?
Who are the key companies in the Global Market for Lupus Therapeutics?
Report Attribute | Details |
---|---|
No. of Pages | 182 |
Published | March 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 3.4 Billion |
Forecasted Market Value ( USD | $ 6.7 Billion |
Compound Annual Growth Rate | 8.8% |
Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned
A selection of companies mentioned in this report includes:
- ADMA Biologics, Inc.
- Amgen, Inc.
- Anthera Pharmaceuticals, Inc.
- Bayer Healthcare AG
- Biogen, Inc.
- Biotest AG
- Bristol-Myers Squibb Company
- Celgene Corporation
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Kedrion Biopharma, Inc.
- LFB Group
- MedImmune, LLC
- Merck KgaA
- Novartis International AG
- Pfizer, Inc.
- Shire PLC
- Takeda Pharmaceuticals Company Ltd.
- UCB SA